Shares of Travere Therapeutics, Inc. (NASDAQ:TVTX – Get Free Report) have received an average recommendation of “Moderate Buy” from the fifteen ratings firms that are presently covering the firm, MarketBeat Ratings reports. Two analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company. The average 12-month target price among brokers that have covered the stock in the last year is $32.14.
Several equities research analysts recently weighed in on TVTX shares. JPMorgan Chase & Co. boosted their target price on Travere Therapeutics from $42.00 to $44.00 and gave the stock an “overweight” rating in a research note on Wednesday, February 26th. Citigroup decreased their target price on Travere Therapeutics from $35.00 to $32.00 and set a “buy” rating for the company in a research note on Wednesday, June 11th. HC Wainwright upgraded Travere Therapeutics to a “buy” rating and set a $30.00 target price for the company in a research note on Wednesday, June 11th. Bank of America boosted their target price on Travere Therapeutics from $29.00 to $31.00 and gave the stock a “buy” rating in a research note on Tuesday, April 1st. Finally, Stifel Nicolaus boosted their target price on Travere Therapeutics from $22.00 to $23.00 and gave the stock a “hold” rating in a research note on Friday, May 2nd.
View Our Latest Report on Travere Therapeutics
Insider Buying and Selling at Travere Therapeutics
Institutional Inflows and Outflows
Institutional investors have recently modified their holdings of the stock. GF Fund Management CO. LTD. acquired a new position in shares of Travere Therapeutics in the fourth quarter valued at approximately $31,000. Sterling Capital Management LLC increased its holdings in shares of Travere Therapeutics by 859.8% in the fourth quarter. Sterling Capital Management LLC now owns 2,361 shares of the company’s stock valued at $41,000 after purchasing an additional 2,115 shares during the period. Caitong International Asset Management Co. Ltd acquired a new position in Travere Therapeutics during the first quarter worth $62,000. Gen Wealth Partners Inc acquired a new position in Travere Therapeutics during the fourth quarter worth $73,000. Finally, KBC Group NV acquired a new position in Travere Therapeutics during the first quarter worth $75,000.
Travere Therapeutics Price Performance
TVTX stock opened at $14.31 on Monday. The business has a 50 day moving average price of $16.90 and a 200 day moving average price of $18.36. The stock has a market cap of $1.27 billion, a price-to-earnings ratio of -5.09 and a beta of 0.75. Travere Therapeutics has a fifty-two week low of $7.36 and a fifty-two week high of $25.29. The company has a quick ratio of 2.03, a current ratio of 2.05 and a debt-to-equity ratio of 9.46.
Travere Therapeutics (NASDAQ:TVTX – Get Free Report) last posted its earnings results on Thursday, May 1st. The company reported ($0.47) earnings per share for the quarter, topping the consensus estimate of ($0.55) by $0.08. The firm had revenue of $81.73 million during the quarter, compared to analysts’ expectations of $77.44 million. Travere Therapeutics had a negative return on equity of 1,179.73% and a negative net margin of 82.88%. The firm’s revenue was up 83.3% compared to the same quarter last year. During the same quarter in the previous year, the business earned ($1.76) earnings per share. Equities research analysts anticipate that Travere Therapeutics will post -1.4 earnings per share for the current fiscal year.
Travere Therapeutics Company Profile
Travere Therapeutics, Inc, a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones.
Recommended Stories
- Five stocks we like better than Travere Therapeutics
- What Does a Stock Split Mean?
- The Boring Is Beautiful Portfolio: 3 Stocks for a Worried World
- 3 Grocery Stocks That Can Help Take a Bite Out of Inflation
- More Than a Monetary Metal: Silver’s Case for Outperformance
- 3 Stocks to Consider Buying in October
- Retail Sales Signal Upside for These 3 Consumer Stocks
Receive News & Ratings for Travere Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Travere Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.